Please use this identifier to cite or link to this item:
Title: Development of an updated, standardized, patient-centered outcome set for lung cancer
Author: De Rooij, Belle H.
Van Den Hurk, Corina
Smaardijk, Veerle
Fernández-Ortega, Paz
Navarro Martin, Arturo
Barberio, Lidia
Guckenberger, Matthias
Schmid, Severin
Walraven, Iris
Vallow, Susan
Kotsi, Christina
Preusser, Matthias
Mosor, Erika
Klok, Jente M.
Becker, Annemarie
Milani, Alessandra
Ninov, Lyudmil
Van De Poll-franse, Lonneke V.
Keywords: Càncer de pulmó
Lung cancer
Issue Date: 29-Aug-2022
Publisher: Elsevier BV
Abstract: Background: In 2016, the International Consortium for Health Outcomes Measurement (ICHOM) defined an international consensus recommendation of the most important outcomes for lung cancer patients. The European Health Outcomes Observatory (H2O) initiative aimed to develop an updated patient-centered core outcome set (COS) for lung cancer, to capture the patient perspective of the impact of lung cancer and (novel) treatments using a combination of patient-reported outcome (PRO) instruments and clinical data as a means to drive value -based health-care. Material and methods: An international, expert team of patient representatives, multidisciplinary healthcare professionals, academic researchers and pharmaceutical industry representatives (n = 17) reviewed potential outcomes generated through literature review. A broader group of patients/patient representatives (n = 31), healthcare professionals / academic researchers (n = 83), pharmaceutical industry representatives (n = 26), and health authority representatives (n = 6) participated in a Delphi study. In two survey rounds, participants scored the relevance of outcomes from a preliminary list. The threshold for consensus was defined as >= 70 % of participants scoring an outcome as highly relevant'. In concluding consensus-meeting rounds, the expert multi-disciplinary team finalized the COS. Results: The preliminary list defined by the core group consisted of 102 outcomes and was prioritized in the Delphi procedure to 64. The final lung cancer COS includes: 1) case-mix factors (n = 27); 2) PROs related to health-related quality of life (HRQoL) (n = 25); 3) clinical outcomes (n = 12). Patient-reported symptoms beyond domains included in the ICHOM lung cancer set in 2016 were insomnia, nausea, vomiting, anxiety, depression, lack of appetite, gastric problems, constipation, diarrhoea, dysphagia, and haemoptysis. Conclusions: We will implement the lung cancer COS in Europe within the H2O initiative by collecting the outcomes through a combination of clinician-reported measures and PRO measures. The COS will support the adoption and reporting of lung cancer measures in a standardized way across Europe and empower patients with lung cancer to better manage their health care.
Note: Reproducció del document publicat a:
It is part of: Lung Cancer, 2022, vol. 173, p. 5-13
Related resource:
ISSN: 1872-8332
Appears in Collections:Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))
Articles publicats en revistes (Infermeria de Salut Pública, Salut mental i Maternoinfantil)

Files in This Item:
File Description SizeFormat 
PIIS0169500222006110.pdf1.24 MBAdobe PDFView/Open

This item is licensed under a Creative Commons License Creative Commons